CTOs on the Move

Ascend Health Services

www.ascend-health.com

 
Ascend Health Services is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ChartWise Medical Systems

Recent changes in Medicare coding requirements have caused hospitals to suffer from lost revenues, penalties and forfeiture of reimbursements due to inadequate documentation. Founder Dr. Jon Elion, who earlier created the highly successful Heartlab imaging software, tackled this problem with an expert team. The result was the company`s premiere product, ChartWise:CDI, which is the first-to-market Computer-Assisted Clinical Documentation Improvement (CACDI) software system designed to improve precision in quality clinical documentation to support revenue assurance. In February 2014 ChartWise launched an upgraded system, ChartWise 2.0—redefining CDI with powerful new features and an advance new user interface. The program is easy for medical professionals to understand and use, has a light IT footprint, and offers hospitals a way to mitigate risk, maximize reimbursement, and gain insight into their medical documentation improvement efforts. No other program is as robust, or addresses the clinical documentation challenges, the way ChartWise 2.0 does.

Vox Nutrition

We are a supplement manufacturer that specialize in private label supplements & custom supplement formulas. Learn about our manufacuring ablitlies here

Eden Village Retirement Ctr

Eden Village Retirement Ctr is a Glen Carbon, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Honors Holdings

Honors Holdings, LLC is a leading franchisee of Orangetheory Fitness studios globally.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.